21 – 30 of 34
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
(
- Contribution to journal › Article
-
Mark
Identification of sequence variants influencing immunoglobulin levels
(
- Contribution to journal › Article
-
Mark
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors : a multicenter IMWG study
(
- Contribution to journal › Article
-
Mark
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone : A pooled analysis
(
- Contribution to journal › Article
-
Mark
Direct evidence for a polygenic etiology in familial multiple myeloma
(
- Contribution to journal › Article
- 2016
-
Mark
Phagocyte Function Decreases after High-Dose Treatment with Melphalan and Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
(
- Contribution to journal › Article
-
Mark
Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma
(
- Contribution to journal › Article
-
Mark
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
(
- Contribution to journal › Article
- 2015
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
(
- Contribution to journal › Article